MINDBREEZE
12.1.2022 10:59:05 CET | Business Wire | Press release
Mindbreeze , a leading provider of appliances and cloud services in the field of information insight, names adesso "European Partner of the Year 2021". Premium partner adesso demonstrated outstanding performance and exceptional implementation expertise in introducing Mindbreeze InSpire.
"adesso has a broad portfolio of technology partnerships. In Mindbreeze, we have a close and strong partner for the segment of enterprise search and insight engines," explains Maximilian Berger, Enterprise Search Manager at adesso. "In our projects, our customers confirm the performance of Mindbreeze InSpire. We are therefore very pleased about the Partner of the Year award - it is a welcome incentive for us to further expand in this segment."
"Mindbreeze Premium Partners are pioneers of digital innovation. We are proud to have such a reliable and competent partner such as adesso on board to turn new ideas into groundbreaking innovations for customers based on Mindbreeze InSpire," explains Daniel Fallmann, founder and CEO of Mindbreeze.
For more information and to register for the Mindbreeze Partner Program, please visit: https://inspire.mindbreeze.com/partner
Mindbreeze InSpire uses a combination of traditional search methods and innovative artificial intelligence approaches (including machine learning, neural networks, speech recognition methods) for the efficient and seamless provision of business-relevant data. The Insight Engine analyzes and interprets enterprise information from connected data sources to provide answers to key business questions.
More than 2,000 of the world's largest companies - including industries such as telecommunications, governmental bodies, aviation, and pharmaceuticals already use Mindbreeze InSpire to achieve their business goals.
About adesso
adesso is one of the leading IT service providers in the German-speaking area and focuses on the core business processes of companies and public administrations with consulting as well as individual software development. The strategy of adesso is based on three pillars: a comprehensive industry know-how of the employees, a broad, vendor-neutral technology competence and proven methods in the implementation of software projects. The results are IT solutions that make companies more competitive. The core industries of adesso are insurance/reinsurance, banking and financial services, health care, lottery, energy supply, public administration, automotive, transport companies and trade. adesso was founded in 1997 in Dortmund and currently employs more than 5,600 people in the adesso Group.
Among the most important customers in the banking sector are Commerzbank, KfW, DZ Bank, Hela-ba, Union Investment, BayernLB and DekaBank, in the insurance sector Munich Re, Hannover Re, DEVK, DAK, Zurich Versicherung, Medizinischer Dienst der Krankenversicherung (MDK-IT) and across all industries Daimler, Bosch, Westdeutsche Lotterie, Swisslos, DZR Deutsches Zahnärztliches Rechenzentrum, TÜV Rheinland, REWAG, Beschaffungsamt des Bundesministeriums des Innern and Bayerisches Staatsministerium der Justiz.
About Mindbreeze
Mindbreeze is a leading international provider of appliances and cloud services for enterprise search, applied artificial intelligence, and knowledge management. The global partner network enables time-zone-independent customer support worldwide. For more information, visit www.mindbreeze.com or follow us on LinkedIn and Twitter @Mindbreeze.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005060/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom